Financial Results: Page 2

Bio-Techne fiscal Q3 sales rise 1% on strength in cell therapy, prostate test products
By Leo O'Connor
Among recent business highlights, the firm noted its ExoDx Prostate test increased its addressable market by approximately 50% after receiving expanded Medicare coverage.
May 3, 2023
Cell Gene Therapy Dna Social
PacBio Q1 revenue rises 17%
By LabPulse.com staff writers
The company received its first orders for the Onso short-read sequencing system and released new workflows in collaboration with Corteva Agriscience that enable the sequencing of thousands of plant and microbial genome samples annually.
May 2, 2023
Dna Sequencing2 Social
QuidelOrtho Q1 revenues drop with lower respiratory testing
By LabPulse.com staff writers
On a supplemental combined basis, first-quarter respiratory testing revenues, including COVID-19 testing, fell 72% year-over-year to $265.6 million from $947.3 million. Non-respiratory testing revenues rose 5% year-over-year.
May 3, 2023
Graph Financial Results Tablet Social
Hologic fiscal Q2 diagnostics revenue drops 53%; firm beats analyst estimates
By Leo O'Connor
Molecular Diagnostics revenue of $342.2 million fell 60% from $862.5 million in the prior year quarter, as COVID-19 testing demand plummeted.
May 1, 2023
Covid 19 Financial Chart Social
Labcorp Q1 revenues drop 3% as base business growth surges
By Leo O'Connor
Growth in the total Base Business, which excluded COVID-19 testing but included revenues from a lab management agreement with Ascension health system, was 19.8% compared to the Base Business in the prior year.
April 27, 2023
Business Financial Results Social
Roche, Thermo Fisher sales drop on diagnostic testing decline in Q1
By Leo O'Connor
Thermo Fisher’s Life Sciences Solutions revenues declined 38% in Q1 compared to the prior-year quarter, but its Analytical Instruments revenues rose 13%.
April 26, 2023
Business Economics Pie Chart Social
Abbott Q1 diagnostics sales decline, but CEO sees milder impact from pandemic
By Leo O'Connor
The impact of COVID-19 on its overall business “has rapidly and significantly lessened,” according to Abbott Chairman and CEO Robert Ford.
April 19, 2023
Business Financial Results Social
Oncocyte to lay off 20% of workforce in cost restructuring
By Leo O'Connor
The CEO said the layoff is part of a plan to bring its cost structure in line with its kitted product strategy and to optimize operational efficiency.
April 13, 2023
Dna Genome Gene Targeted Social
SomaLogic CEO steps down; Q4 revenue declines 18%
By Leo O'Connor
SomaLogic is at a stage where it needs "seasoned leaders to accelerate market adoption," said Troy Cox, executive chairman of the board of directors.
March 29, 2023
Business Financial Results Social
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
By Leo O'Connor
The firm recorded an accounting impairment in Q4 for excess manufacturing and inventory related to the scale-up during peak COVID-19 testing demand and the decision to pause commercialization of its Amira COVID-19 test.
March 21, 2023
Business Financial Stock Drop Social
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
By Leo O'Connor
The company’s revenues have come predominantly from its COVID-19 testing product, but it is "executing well" on its strategy of expanding the test menu, CEO Ayub Khattak said.
March 16, 2023
Business Financial Results Social
Quanterix Q4 revenues drop 15% but match analysts’ expectations
By Leo O'Connor
For full-year 2022, total revenue was $105.5 million, a decline of 5% compared with 2021 revenue that included $5.2 million in National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) grant money.
March 6, 2023
Business Financial Results Social
Previous Page
Page 2 of 12
Next Page